BUYUN LIU(Tony)

• Legal representative responsible for overall management and business expansion of the Turkey branch
• Manages a team of over 40 employees, 90% of whom are local; successfully restructured 80% of staff and doubled the team size during tenure
• Achieved exceptional sales growth despite Turkish currency devaluation: 2022: $14M 2023: $30M 2024: $35M 2025 Est: $40M
• Oversees Mindray’s complete product lines in Turkey, including In-Vitro Diagnostics, Patient Monitoring, and Ultrasound, managing over 30 local distributors and 700+ end customers including the Ministry of Health and private medical groups
• Leads local platform development and cross-functional operations (finance, legal, HR, logistics), ensuring stable, compliant, and healthy business growth

Awards:

• 2023: Mindray Outstanding Branch
• 2023: Annual Outstanding Manager
• 2023: Performance Rating A+

• Responsible for sales of IVD products across 7 Eastern European countries; based in Poland from 2020
• Developed and empowered regional distributors to execute sales strategies and promotional plans
• Built a local team of 7 foreign staff from scratch (starting 2019)
• Achieved annual sales targets (except 2020); broke into top 10 European lab chains (Unilabs, Synevo, Medirex, Synlab, Diagnostika), significantly increasing market share: Poland: 17.9%, Slovakia: 67.3%, Czech Republic: 32.8%
• Participated in pricing and product strategy formulation, organized marketing events and academic exchanges

Awards:

• 2018: Company-level Top Sales
• 2019 & 2021: Annual Outstanding Employee
• 2018, 2019, 2021: Performance Rating A/A+

• Based in Germany during 2016, helped establish Wondfo's local office
• Expanded into untapped markets in Central Europe; responsible for key accounts in prenatal care, drug tests, and quantitative diagnostics products.

• Led Mindray to secure a major tender from the Turkish Ministry of Health in 2023: Included 1900+ patient monitors and 400+ anesthesia machines across 200+ public hospitals in 40 provinces, total project value exceeded $10M
• In 2024, after 10 years Mindray again won the high-end Resona R series ultrasound systems from MoH procurement: 192 units deployed to 200+ hospitals in 20 provinces, project value exceeded $6M

• Upon arrival in 2022, led reform of a 7-year exclusive distributor setup that hindered growth
• Within 3 months, personally visited over 50 potential distributors nationwide with frontline staff
• Created a screening funnel and provided rational risk analysis to HQ
• Replaced exclusive model with 4 regional distributors, achieving smooth transition and significant growth: Mindray Turkish IVD product line sales rise from $4M (2022) to $15M (2025)

• Inherited an underperforming branch in 2022 with flat $15M revenue over 10 years and only 18 staff
• By 2025: Sales projected at $40M Team size reached 45 Staff turnover dropped from 76% (2023) to 15% (Q1 2025)
• Achievements: 2023: Outstanding Branch 2023: Outstanding Manager 2024: Outstanding Deputy General Manager System-level awards for multiple product teams including IVD, PMLS, MIS and Service

• Broke into Poland’s largest (Diagnostyka) and second-largest (Alab) lab chains for hematology projects
• Using New product BC-6 series entered AlphaMedical, Medirex, Agel labs in Czechia and Slovakia
• Slovakia hematology market share rose from 12% to 67% within two years